Baird Financial Group, Inc. Corcept Therapeutics Inc Transaction History

Baird Financial Group, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$22.21 - $34.48 $80,799 - $125,438	3,638 Added 11.29%	35,859 $1.17 Million
Q1 2024 May 14, 2024	BUY	$21.1 - $27.46 $679,863 - $884,788	32,221 New	32,221 $811,000
Q3 2023 Nov 13, 2023	BUY	$21.97 - $33.8 $511,329 - $786,661	23,274 New	23,274 $634,000
Q1 2023 May 15, 2023	BUY	$19.2 - $24.47 $91,641 - $116,795	4,773 Added 27.96%	21,841 $473,000
Q3 2022 Nov 14, 2022	BUY	$24.7 - $29.12 $232,599 - $274,223	9,417 New	9,417 $241,000
Q4 2019 Feb 14, 2020	SELL	$12.06 - $16.96 $1.54 Million - $2.17 Million	-127,828 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$10.41 - $14.66 $198,914 - $280,123	-19,108 Reduced 13.0%	127,828 $1.81 Million
Q2 2019 Aug 14, 2019	BUY	$9.78 - $12.76 $1.44 Million - $1.87 Million	146,936 New	146,936 $1.64 Million

355

86.2M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $7.17B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Baird Financial Group, Inc. with notifications on news.